Oxford BioTherapeutics Licenses WuXi Biologics’ WuXiBody Platform for Five Bispecific Antibodies

 Oxford BioTherapeutics Licenses WuXi Biologics’ WuXiBody Platform for Five Bispecific Antibodies

Oxford BioTherapeutics Licenses WuXi Biologics’ WuXiBody Platform for Five Bispecific Antibodies

Shots:
  • Wuxi  to receive upfront, $450M milestone and royalties on sales from Oxford BioTherapeutics. Oxford to get rights for WuXi Biologics’ WuXiBody platform to develop and commercialize five Bispecific Abs for cancer
  • The focus of the agreement is to develop cancer therapies by combining WuXiBody platform with PDL1 Ab with reduction in cost & risk rates
  • WuXiBody platform is a bispecific Ab technology with structural flexibility, assess in development of Abs with different valency (2, 3 or 4 binding sites) for multiple therapeutic area

Click here to read full press release/ article | Ref: Oxford Biotherapeutics | Image: Contract pharma

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post